Saliha Kanık YÜKSEK, Hasan TEZER, Aslınur Özkaya PARLAKAY, Belgin GÜLHAN, Ateş KARA, Ergin ÇİFTÇİ, Anıl TAPISIZ, Melda ÇELİK, Halil ÖZDEMİR, Kübra AYKAÇ, Tuğba Bedir DEMİRDAĞ, Tuğçe Tural KARA, Gamze HAYRAN, Erdal İNCE

Impact of the mandatory Hepatitis A immunization program: before and after the vaccine in Ankara, Central of Turkey

In Turkey Hepatitis A virus (HAV) infection is considered to be moderateendemic. Hepatitis A vaccine was included in the mandatory vaccinationschedule of Turkey on November 2012. We aimed to evaluate the cases of HAVinfection followed in Ankara, which is located in the center of Central Anatolia,retrospectively according to the date of the administration of the mandatoryhepatitis A vaccine. A total of 272 children followed-up between January 2008and December 2015 for HAV infection in five separate hospitals were enrolledto the study. There were 200 (68.2%) cases in the pre-vaccination group, 72(31.74%) cases in the post-vaccination group, and 55.1% were male in total.The immunization status were as follow; 89.7% (n = 244) unvaccinated, 0.4%(n = 1) vaccinated and 9.9% (n = 27) with unknown immune status. Therewas a statistically significant difference between the groups in hospitalizationrates, but no statistically significant differences in hospitalization indications,length of hospital stay, complication types and proportions, and normalizationperiod of transaminases. The national hepatitis A immunization program inTurkey has had a significant impact when the targeted population is considered,with suggestive herd protection effects.

PDF

___

1. Matheny SC, Kingery JE. Hepatitis A. Am Fam Physician 2012; 86: 1027-1034.

2. Karaman S, Karaman K, Kızılyıldız BS, et al. Seroprevalence of hepatitis a and associated factors among 1-15 year old children in Eastern Turkey. Int J Clin Exp Med 2015; 8: 19394-19399.

3. Kara Hİ. Akut Viral Hepatit A. Türk Aile Hek Derg 2007; 11: 177-184.

4. WHO position paper on hepatitis A vaccines – June 2012. Wkly Epidemiol Rec 2012; 87: 261-276.

5. Ximenes RA, Martelli CM, Amaku M, et al; Hepatitis Study Group. Modelling the force of infection for hepatitis A in an urban population-based survey: a comparison of transmission patterns in Brazilian macro-regions. PLoS One 2014; 9: e94622.

6. Lima LR, De Almeida AJ, Tourinho Rdos S, Hasselmann B, Ximenez LL, De Paula VS. Evidence of hepatitis A virus person-to-person transmission in household outbreaks. PLoS One 2014; 9: e102925.

7. Havelaar AH, Kirk MD, Torgerson PR, et al; World Health Organization Foodborne Disease Burden Epidemiology Reference Group. World Health Organization Global Estimates and Regional Comparisons of the Burden of Foodborne Disease in 2010. PLoS Med 2015; 12: e1001923.

8. Lozano R, Naghavi M, Foreman K, et al. Globaland regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-2128.

9. Vitral CL, Ospina FL, Artimos S, et al. Decliningprevalence of hepatitis A virus antibodies among children from low socio-economic groups reinforces the need for the implementation of hepatitis A vaccination in Brazil. Mem Inst Oswaldo Cruz 2012; 107: 652-658.

10. Carlos F, Gómez JA, Anaya P, Romano-Mazzotti L. Health economic assessment of universal immunization of toddlers against Hepatitis AVirus (HAV) in Mexico. Hum Vaccin Immunother 2016; 12: 52-63.

11. Zhuang FC, Qian W, Mao ZA, et al. Persistent efficacy of live attenuated hepatitis A vaccine (H2-strain)after a mass vaccination program. Chin Med J (Engl) 2005; 118: 1851-1856.

12. Martínez A, Broner S, Sala MR, et al; and the Working Group for the Study Hepatitis a in Catalonia. Changes in the epidemiology of hepatitis A outbreaks 13 years after the introduction of a mass vaccination program. Hum Vaccin Immunother 2015; 11: 192-197.

13. Van Herck K, Van Damme P. Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence. J Med Virol 2001; 63: 1-7.

14. Ogholikhan S, Schwarz KB. Hepatitis vaccines. Vaccines (Basel) 2016; 4: doi: 10.3390.

15. Daniels D, Grytdal S, Wasley A. Surveillance for acute viral hepatitis - United States, 2007. MMWR Surveill Summ 2009; 58: 1-27.

16. Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 2005; 294: 202-210.

17. Chodick G, Heymann AD, Ashkenazi S, Kokia E, Shalev V. Long-term trends in hepatitis A incidence following the inclusion of Hepatitis A vaccine in the routine nationwide immunization program. J Viral Hepat 2008; 15: 62-65.

18. Vacchino MN. Incidence of hepatitis A in Argentina after vaccination. J Viral Hepat 2008; 15: 47-50.

19. Molina Merino A, Martínez-Huguet F, Asensi Monzó MT, Brines Solanes J, Codoñer Franch P. Cholestatictype hepatitis in childhood. An Esp Pediatr 1998; 49: 253-256.

20. Jelić O, Fornet-Sapcevski J, Kovacevíc L, Pandak N, Jelić D. Recurrences of viral hepatitis A. Acta Med Iugosl 1990; 44: 565-576.

21. Polson J, Lee WM; American Association for the Study of Liver Disease. American Association for the Study of Liver D: AASLD Position Paper: The Management of Acute Liver Failure. Hepatology 2005; 41: 1179- 1197.

22. Yoldaş Ö, Bulut A, Altındiş M. Hepatit A enfeksiyonlarına güncel yaklaşım. Viral Hepatit Dergisi 2012; 18: 81-86.

23. Alhan E, Kozanoğlu B, Tümgör G, Çelik Ü, Yaman A, Bozdemir N. Epidemiological shift of hepatitis A in central Adana, Turkey. Turk J Gastroenterol 2014; 25: 6-8.

24. Ministry of Health of the Republic of Turkey, Public Health Institution of Turkey. Statistical Data of Department of Preventable Diseases with Vaccine, 30 March 2016, Available at: https://www.thsk. gov.tr/component/k2/353-istatiksel-veriler/asi-ileonlenebilir-hastaliklar-daire-baskanligi-istatikselverileri.html. (last accessed 15 September 2018)

25. Van Effelterre T, De Antonio-Suarez R, Cassidy A, Romano-Mazzotti L, Marano C. Model-based projections of the population-level impact of hepatitis A vaccination in Mexico. Hum Vaccin Immunother 2012; 8: 1099-1108.

26. Thompson C, Dey A, Fearnley E, Polkinghorne B, Beard F. Impact of the national targeted Hepatitis A immunisation program in Australia: 2000-2014. Vaccine 2017; 35: 170-176.

27. Mellou K, Sideroglou T, Papaevangelou V, et al. Considerations on the current universal vaccination policy against hepatitis A in Greece after recent outbreaks. PLoS One 2015; 10: e0116939.

28. Martinelli D, Bitetto I, Tafuri S, Lopalco PL, Mininni RM, Prato R. Control of hepatitis A by universal vaccination of children and adolescents: an achieved goal or a deferred appointment? Vaccine 2010; 28: 6783-6788.

29. Jacobs RJ, Greenberg DP, Koff RS, Saab S, Meyerhoff AS. Regional variation in the cost effectiveness of childhood hepatitis A immunization. Pediatr Infect Dis J 2003; 22: 904-914.

30. Valenzuela MT, Jacobs RJ, Arteaga O, Navarrete MS, Meyerhoff AS, Innis BL. Cost-effectiveness of universal childhood hepatitis A vaccination in Chile. Vaccine 2005; 23: 4110-4119.

31. Quezada A, Baron-Papillon F, Coudeville L, Maggi L. Universal vaccination of children against hepatitis A in Chile: a cost-effectiveness study. Rev Panam Salud Publica 2008; 23: 303-312.